Tamtam Try Tamtam free
Ottobock logo

Ottobock account plan

Advanced prosthetics orthotics mobility

At a glance

Ottobock is a German maker of prosthetics, orthotics and exoskeletons with a patient care network; 2025 revenue was € 1,679.8 million.

Ottobock SE & Co. KGaA, based in Duderstadt, Germany, develops and makes prosthetics, neuro-orthotics, digital orthotics and prosthetics (O&P) solutions and occupational exoskeletons, and runs the Ottobock.care network of over 420 clinics and satellites in 33 countries. Its customers are O&P professionals, distributors, public institutions and amputee and neurological patients; with partners it reached patients in more than 132 countries in 2025. FY2025 revenue was € 1,679.8 million (+4.7%), core revenue € 1,599.7 million and underlying core EBITDA € 415.3 million (26.0% margin), with an average headcount of 9,275 FTE. It has been listed on the Frankfurt Stock Exchange since 9 October 2025; the Näder Family Office holds 82.44%.

Business units

Strategic priorities

Innovation and reimbursement
Ottobock aims to advance the standard of care in prosthetics and neuro-orthotics through new products and reimbursement wins; it launched 29 new or upgraded products in 2025 and the michelangelo hand, iconiq liner and C-Brace Interim at OTWorld in 2026.
Patient care network expansion
Forward integration to expand, integrate and digitalise the B2C network, including the Ottobock.care brand roll-out, IT harmonisation in U.S. clinics and acquisitions such as Blatchford Norway and Rehattiva.
Operational efficiency
The GVEM programme, the Bulgarian shared service center and SAP S/4HANA support a margin target of 29 to 30% adjusted EBITDA in 2029.
Digital O&P and AI
Ottobock is building an end-to-end digital patient care chain, with AI-supported Smart Documentation launched in 2025 and AI tools now preparing reimbursement approval requests.
Portfolio focus
The Human Mobility wheelchair business is being sold to DH Care with closing targeted by year-end, so that from 2027 Ottobock reports only its core business.

Latest results

In January-September 2026 revenue rose 7.4% to € 1,307.9 million and core revenue 8.1% to € 1,251.8 million, with organic core growth of 6.6%. Underlying core EBITDA rose 16.4% to € 327.1 million, a 26.1% margin, and net income reached € 115.1 million. Q3 was partly below management's expectation because of a tougher reimbursement environment in Western Europe and the U.S. The 2026 guidance of 6%-8% organic core growth and an underlying core EBITDA margin above 27.0% was confirmed, though the CEO expects full-year growth between 6% and 7%.

Investments and deals

Blatchford Norway acquisition
On 13 May 2026 Ottobock bought 100% of Blatchford Norway AS, a Norwegian patient care brand, for € 115.3 million in cash.
Fesia and Rehattiva acquisitions
In July 2026 Ottobock agreed to buy Fesia Technology S.L. (Spain, functional electrical stimulation) for a preliminary € 15.0 million plus earn-out, and acquired Rehattiva Srl, an Italian patient care business.
Neural interface ventures
A € 4.4 million stake in Blue Arbor Technologies in February 2026, following 2025 stakes in Bionic Skins, Musclemetrix and Phantom Neuro and a € 10.0 million follow-on in ONWARD Medical.
Capex and R&D
CapEx was € 105.2 million in 2025 and R&D expenses € 72.7 million plus € 54.1 million capitalised; net CapEx and capitalised R&D stay at EUR 105-150 million for 2026.
IPO
The October 2025 IPO at € 66.00 per share placed 12,236,173 shares (€ 807.6 million).

Challenges and risks

Tighter reimbursement
Germany plans a reduction of approximately 3% in reimbursement rates from 2027, France cut the price of the C-Leg and Belgium cut its budget; converting a patient to revenue now takes about three months instead of one.
U.S. approval delays and destocking
The Genium X4 is reimbursed under a miscellaneous code, so each fitting needs separate approval, and U.S. customers adjusted inventories.
Russia exposure
Russia was more than 11% of group revenue in January-September 2026, bringing sanctions risk and short-seller allegations that the CFO rejects.
Supply and cyber risks
The largest risks in the 2025 matrix are supplier dependencies and supply shortages, IT failures from cyber-attacks and data protection penalties.
Slower patient care growth
B2C organic growth of 3.3% in nine months was below the company's ambition, partly due to longer approvals in Germany, France and Belgium.

What leadership says

“Our success is based on the interplay of technological excellence, integrated value creation, and immediate proximity to application”

Oliver Jakobi, CEO and Chief Sales Officer · Interview in the Annual Report 2025, March 2026

“A 3% haircut, what we are now expecting in Germany, a year ago, was not anticipated.”

Oliver Jakobi, CEO and Chief Sales Officer · Q3 2026 earnings call, 12 November 2026

“Strategically and operationally, we are fully on track.”

Oliver Jakobi, CEO · H1 2026 earnings call, 13 August 2026

“We're not expecting a margin decline”

Dr. Arne Kreitz, CFO · Q3 2026 earnings call, 12 November 2026, on 2027

Where a supplier can help

Reimbursement automation
Tied to tighter reimbursement and U.S. approval delays: documentation, payer-communication and revenue-cycle tools can shorten the approval period Ottobock is already tackling with AI.
Clinic IT and integration
Tied to patient care network expansion and recent acquisitions: clinic management software, IT harmonisation and integration services fit the growing Ottobock.care network.
Finance and ERP transformation
Tied to operational efficiency: the SAP S/4HANA implementation and the Bulgarian shared service center create needs for ERP, process and shared-services suppliers.
Supply chain resilience
Tied to supplier dependencies and supply shortages: second sourcing, components and supply chain visibility tools address the top-ranked risk.
Cybersecurity and data protection
Tied to cyber and GDPR/NIS-2 risks: security and compliance providers fit a group running clinics and connected products.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Ottobock?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Ottobock

What does Ottobock do?

Ottobock develops and makes prosthetics, neuro-orthotics, digital O&P solutions and exoskeletons, and fits patients through its Ottobock.care network of over 420 clinics and satellites in 33 countries.

What is Ottobock's revenue?

FY2025 revenue was € 1,679.8 million (+4.7%). In January-September 2026 revenue was € 1,307.9 million (+7.4%).

How many employees does Ottobock have?

Average headcount was 9,275 FTE in 2025 and average FTE was 9,455 in January-September 2026.

Who leads Ottobock?

Oliver Jakobi is CEO and Chief Sales Officer, Dr. Arne Kreitz is CFO, and Prof. Hans Georg Näder chairs the Management Board of the general partner.

What is Ottobock's strategy?

Three pillars: innovation and technology leadership scaled through B2B, forward integration of the patient care network, and operational excellence, with a target of 29 to 30% adjusted EBITDA margin in 2029.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)